Methotrexate and mucositis: A merry-go-round for oncologists

Kundan Mishra; Aditya Jandial; Anil Kumar; Deepesh Lad; Gaurav Prakash; Alka Khadwal; Pankaj Malhotra

doi:10.4103/ijmpo.ijmpo_113_18

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(01): 150-152
DOI: 10.4103/ijmpo.ijmpo_113_18

Practitioner Section

Methotrexate and mucositis: A merry-go-round for oncologists

Authors

Kundan Mishra

Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Aditya Jandial

Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Anil Kumar

Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Deepesh Lad

Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Gaurav Prakash

Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Alka Khadwal

Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Pankaj Malhotra

Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Abstract

High-dose methotrexate is the backbone of various regimens for treating lymphoid malignancies. Mucositis is a well-known, dose-related side effect of methotrexate. Prophylactic measures such as folinic acid rescue are useful but do not prevent mucositis in all the cases. Once severe mucositis (WHO Grade IV) sets in, mortality is very high. The index case highlights the natural course of methotrexate-induced mucositis and the need for swift and preemptive intervention.

Keywords

Lymphoid malignancy - methotrexate - mucositis

Full Text

References

References
1 Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948; 238: 787-93
2 Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist 2016; 21: 1471-82
3 Rask C, Albertioni F, Schrøder H, Peterson C. ral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: Relation to pharmacokinetic parameters of methotrexate. Pediatr Hematol Oncol 1996; 13: 359-67
4 Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M. et al. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100: 1995-2025
5 Goldin A, Venditti JM, Kline I, Mantel N. Mantel N. Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor. Nature 1966; 212: 1548-50
6 Schmidt S, Thoennissen NH, Rudat A, Bieker R, Schliemann C, Mesters RM. et al. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann Oncol 2008; 19: 1644-9
7 Schwartz S, Borner K, Müller K, Martus P, Fischer L, Korfel A. et al. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist 2007; 12: 1299-308
8 Ramsey LB, Balis FM, O'Brien MM, Schmiegelow K, Pauley JL, Bleyer A. et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist 2018; 23: 52-61
9 Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM. et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120: 1453-61